Company / Operating Cash Flow
ENANTA PHARMACEUTICALS INC Operating Cash Flow History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
-$103.2M
FY2025
5-year range
-$103.2M / $71.4M
FY2021-FY2025
Trend
-21.7%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Operating Cash Flow has declined for 4 consecutive years, from $71M in FY2021 to -$103M in FY2025.
Based on SEC 10-K filings.
-$103M in FY2025.
Declined from -$70M to -$103M over the past 2 years.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- ENANTA PHARMACEUTICALS INC's operating cash flow has declined for 4 consecutive years.
- In FY2025, operating cash flow decreased 21.7% year-over-year.
- Peak operating cash flow was recorded in FY2017.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -0.48 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$103.2M | -21.7% |
| FY2024 | -$84.8M | -21.1% |
| FY2023 | -$70.0M | -1087.5% |
| FY2022 | $7.1M | -90.1% |
| FY2021 | $71.4M | +144.4% |
| FY2020 | $29.2M | -44.5% |
| FY2019 | $52.7M | +47.0% |
| FY2018 | $35.8M | -53.3% |
| FY2017 | $76.7M | +280.0% |
| FY2016 | $20.2M | +89.4% |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026